

參考資料

1. Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. *Am J Hosp Palliat Care* 2012; 29:70-9.
2. Khan MI, Walsh D, Brito-Dellan N. Opioid and adjuvant analgesics: compared and contrasted. *Am J Hosp Palliat Care* 2011; 28:378-83.
3. van den Beuken-van Everdingen MH, de Graeff A, Jongen JL, et al. Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. *Pain Pract* 2017; 17:409-19.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain, Version 1.2018. 2018.
5. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. *J Pain Symptom Manage* 2001; 21:144-50.
6. Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. *Pain* 2012; 153:359-65.
7. McDonald AA, Portenoy RK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. *J Support Oncol* 2006; 4:43-52.
8. Bredlau AL, Thakur R, Korones DN, et al. Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature. *Pain Med* 2013; 14:1505-17.
9. Tsui PY, Chu MC. Ketamine: an old drug revitalized in pain medicine. *BJA Education* 2017; 17:84-7.
10. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. *Br J Clin Pharmacol* 2014; 77:357-67.
11. Zgaia AO, Irimie A, Sandesc D, et al. The role of ketamine in the treatment of chronic cancer pain. *Clujul Med* 2015; 88:457-61.
12. Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? *Curr Opin Support Palliat Care* 2017; 11:88-92.
13. Mannino R, Coyne P, Swainey C, et al. Methadone for cancer-related neuropathic pain: a review of the literature. *J Opioid Manag* 2006; 2:269-76.
14. McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. *Cochrane Database Syst Rev* 2017; 5:CD012499.
15. Leppert W, Buss T. The role of corticosteroids in the treatment of pain in cancer patients. *Curr Pain Headache Rep* 2012; 16:307-13.
16. Haywood A, Good P, Khan S, et al. Corticosteroids for the management of cancer-related pain in adults. *Cochrane Database Syst Rev* 2015; (4):CD010756.
17. Lin KT, Wang LH. New dimension of glucocorticoids in cancer treatment. *Steroids* 2016; 111:84-8.
18. Mika J, Zychowska M, Makuch W, et al. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. *Pharmacol Rep* 2013; 65:1611-21.
19. Obata H. Analgesic Mechanisms of Antidepressants for Neuropathic Pain. *Int J Mol Sci* 2017; 18(11). doi: 10.3390/ijms18112483.
20. Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. *Expert Opin Pharmacother* 2010; 11:2813-25.

21. Guan J, Tanaka S, Kawakami K. Anticonvulsants or Antidepressants in Combination Pharmacotherapy for Treatment of Neuropathic Pain in Cancer Patients: A Systematic Review and Meta-analysis. *Clin J Pain* 2016; 32:719-25.
22. Murnion BP. Neuropathic pain: current definition and review of drug treatment. *Aust Prescr* 2018; 41:60-3.
23. Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. In: Pratt V, McLeod H, Rubinstein W, et al., eds. *Medical Genetics Summaries*. 2017. US National Center for Biotechnology Information, Bethesda MD, USA. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK425165/> [Accessed July 02, 2018]
24. Vadalouca A, Raptis E, Moka E, et al. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. *Pain Pract* 2012; 12:219-51.
25. Litzinger MHJ, Takeshita J, Litzinger M. SSRIs and Serotonin Syndrome. *US Pharm* 2008; 33:29-37.
26. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database Syst Rev* 2014; (1):CD007115.
27. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015; 14:162-73.
28. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. *Palliat Med* 2011; 25:553-9.
29. McGeeney BE. Adjuvant agents in cancer pain. *Clin J Pain* 2008; 24:S14-20.
30. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. *Nature* 2004; 428:486.
31. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics* 2006; 16:297-306.
32. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. *N Engl J Med* 2011; 364:1126-33.
33. Lin CH, Lu CH, Wang FJ, et al. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. *Clin Neuropharmacol* 2010; 33:293-6.
34. Kim YS, Kim DW, Jung KH, et al. Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia. *Seizure* 2014; 23:208-12.
35. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. *JAMA* 2016; 315:1624-45.
36. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. *Epilepsia* 2004; 45 Suppl 6:13-8.
37. Raptis E, Vadalouca A, Stavropoulou E, et al. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. *Pain Pract* 2014; 14:32-42.
38. National Comprehensive Cancer Network (NCCN). *NCCN Clinical Practice Guidelines in Oncology: Survivorship, Version 2.2017*. 2017.
39. Zaporowska-Stachowiak I, Łuczak J, Hoffmann K, et al. Managing

- metastatic bone pain: New perspectives, different solutions. *Biomed Pharmacother* 2017; 93:1277-84.
40. Coleman R. The use of bisphosphonates in cancer treatment. *Ann N Y Acad Sci* 2011; 1218:3-14.
 41. Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis. *Cancer Treatment Reviews* 2013; 39:97-104.
 42. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011; 29:1125-32.
 43. Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. *Clin Cancer Res* 2012; 18:4841-9.
 44. Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. *Eur J Pharmacol* 2001; 429:71-78.
 45. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. *Cochrane Database Syst Rev* 2017; 6:CD003351.